Cue Biopharma is trading 5% higher at $32.48, amid continued volatility following the September 20 CUE-221 Phase 2 results and broader biotech strength. - The study met its primary and key secondary endpoints. - XBI was up 2.07% during regular trading. - The rebound follows a 9.30% gain on September 22 and a 23.70% decline on September 21. No new company-specific announcement or reliable late-breaking catalyst was identified for September 23, 2026.